Knowledge Center
Article / Oct 01, 2012
New Technologies in Particle Design. Interview: Colin Minchom, VP, Particle Design Business Unit
Source:
Drug Development and Delivery, October 2012
“An issue for customers with a poorly soluble molecule is that any one solubility enhancement technology is likely to have, I believe, a 20% to 40% probability of solving the problem. This means that in order to assure acceptable bioavailability, at least three technologies need to be investigated. The customer would need to contract with three single platform technology companies or be able to engage a single company, such as ɫAV, that can apply multiple platforms, to increase the probability of solving the problem, and deliver the desired outcome.”
Related links
Also in the Knowledge Center
/ Mar 01, 2023
Framework for the validation of mechanistic and hybrid models as Process Analytical tools in the pharmaceutical Industry
Read more
Scientific Article
Scientific Article
/ Aug 03, 2023
Nasal-PAMPA: A novel non-cell-based high throughput screening assay for prediction of nasal drug permeability
Read more
Scientific Article